Glycated albumin at 4 weeks correlates with a1c levels at 12 weeks and reflects short-term glucose fluctuations

Cyrus V Desouza, Julio Rosenstock, Rong Zhou, Richard G. Holcomb, Vivian A. Fonseca

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: Evaluate the performance of glycated albumin (GA) monitoring by comparing it to other measures of glycemic control during intensification of antidiabetic therapy. Methods: This 12-week, prospective, multicenter study compared the diagnostic clinical performance of GA to glycated hemoglobin A1C (A1C), fructosamine corrected for albumin (FRA), fasting plasma glucose (FPG), and mean blood glucose (MBG) estimated from self-monitoring of blood glucose (SMBG) and continuous glucose monitoring (CGM) in 30 patients with suboptimally controlled type 1 or 2 diabetes. Results: Mean A1C decreased from 9.5% to 8.1%. Mean SMBG correlated closely with CGM (Pearson r = 0.783 for daily estimates and r = 0.746 for weekly estimates, P<.0001). Both GA and FRA levels significantly correlated with changes from baseline in A1C and mean weekly SMBG (P<.001). The lowest observed median GA occurred at 4 weeks, followed by a small increase and then a slight reduction, mirroring changes in overall mean SMBG values. The median A1C fell throughout the treatment period, failing to reflect short-term changes in SMBG. A ≥1% reduction in GA at 4 weeks was significantly associated with a ≥0.5% change in A1C at 12 weeks (odds ratio [OR] = 19.0, 95% confidence interval [CI]: 1.4, 944, P =.018). Conclusion: In patients receiving glucose-lowering therapy, changes in GA at 4 weeks were concordant with changes in A1C at 12 weeks, and both GA and FRA more accurately reflected short-term blood glucose fluctuations than A1C.

Original languageEnglish (US)
Pages (from-to)1195-1203
Number of pages9
JournalEndocrine Practice
Volume21
Issue number11
DOIs
StatePublished - Nov 2015

Fingerprint

Blood Glucose Self-Monitoring
Glucose
Blood Glucose
Albumins
Fructosamine
Glycosylated Hemoglobin A
glycosylated serum albumin
Type 1 Diabetes Mellitus
Hypoglycemic Agents
Serum Albumin
Type 2 Diabetes Mellitus
Multicenter Studies
Fasting
Therapeutics
Odds Ratio
Prospective Studies
Confidence Intervals

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Glycated albumin at 4 weeks correlates with a1c levels at 12 weeks and reflects short-term glucose fluctuations. / Desouza, Cyrus V; Rosenstock, Julio; Zhou, Rong; Holcomb, Richard G.; Fonseca, Vivian A.

In: Endocrine Practice, Vol. 21, No. 11, 11.2015, p. 1195-1203.

Research output: Contribution to journalArticle

Desouza, Cyrus V ; Rosenstock, Julio ; Zhou, Rong ; Holcomb, Richard G. ; Fonseca, Vivian A. / Glycated albumin at 4 weeks correlates with a1c levels at 12 weeks and reflects short-term glucose fluctuations. In: Endocrine Practice. 2015 ; Vol. 21, No. 11. pp. 1195-1203.
@article{39e1e2c65052446aaa7cde348fea87b1,
title = "Glycated albumin at 4 weeks correlates with a1c levels at 12 weeks and reflects short-term glucose fluctuations",
abstract = "Objective: Evaluate the performance of glycated albumin (GA) monitoring by comparing it to other measures of glycemic control during intensification of antidiabetic therapy. Methods: This 12-week, prospective, multicenter study compared the diagnostic clinical performance of GA to glycated hemoglobin A1C (A1C), fructosamine corrected for albumin (FRA), fasting plasma glucose (FPG), and mean blood glucose (MBG) estimated from self-monitoring of blood glucose (SMBG) and continuous glucose monitoring (CGM) in 30 patients with suboptimally controlled type 1 or 2 diabetes. Results: Mean A1C decreased from 9.5{\%} to 8.1{\%}. Mean SMBG correlated closely with CGM (Pearson r = 0.783 for daily estimates and r = 0.746 for weekly estimates, P<.0001). Both GA and FRA levels significantly correlated with changes from baseline in A1C and mean weekly SMBG (P<.001). The lowest observed median GA occurred at 4 weeks, followed by a small increase and then a slight reduction, mirroring changes in overall mean SMBG values. The median A1C fell throughout the treatment period, failing to reflect short-term changes in SMBG. A ≥1{\%} reduction in GA at 4 weeks was significantly associated with a ≥0.5{\%} change in A1C at 12 weeks (odds ratio [OR] = 19.0, 95{\%} confidence interval [CI]: 1.4, 944, P =.018). Conclusion: In patients receiving glucose-lowering therapy, changes in GA at 4 weeks were concordant with changes in A1C at 12 weeks, and both GA and FRA more accurately reflected short-term blood glucose fluctuations than A1C.",
author = "Desouza, {Cyrus V} and Julio Rosenstock and Rong Zhou and Holcomb, {Richard G.} and Fonseca, {Vivian A.}",
year = "2015",
month = "11",
doi = "10.4158/EP14570.OR",
language = "English (US)",
volume = "21",
pages = "1195--1203",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "11",

}

TY - JOUR

T1 - Glycated albumin at 4 weeks correlates with a1c levels at 12 weeks and reflects short-term glucose fluctuations

AU - Desouza, Cyrus V

AU - Rosenstock, Julio

AU - Zhou, Rong

AU - Holcomb, Richard G.

AU - Fonseca, Vivian A.

PY - 2015/11

Y1 - 2015/11

N2 - Objective: Evaluate the performance of glycated albumin (GA) monitoring by comparing it to other measures of glycemic control during intensification of antidiabetic therapy. Methods: This 12-week, prospective, multicenter study compared the diagnostic clinical performance of GA to glycated hemoglobin A1C (A1C), fructosamine corrected for albumin (FRA), fasting plasma glucose (FPG), and mean blood glucose (MBG) estimated from self-monitoring of blood glucose (SMBG) and continuous glucose monitoring (CGM) in 30 patients with suboptimally controlled type 1 or 2 diabetes. Results: Mean A1C decreased from 9.5% to 8.1%. Mean SMBG correlated closely with CGM (Pearson r = 0.783 for daily estimates and r = 0.746 for weekly estimates, P<.0001). Both GA and FRA levels significantly correlated with changes from baseline in A1C and mean weekly SMBG (P<.001). The lowest observed median GA occurred at 4 weeks, followed by a small increase and then a slight reduction, mirroring changes in overall mean SMBG values. The median A1C fell throughout the treatment period, failing to reflect short-term changes in SMBG. A ≥1% reduction in GA at 4 weeks was significantly associated with a ≥0.5% change in A1C at 12 weeks (odds ratio [OR] = 19.0, 95% confidence interval [CI]: 1.4, 944, P =.018). Conclusion: In patients receiving glucose-lowering therapy, changes in GA at 4 weeks were concordant with changes in A1C at 12 weeks, and both GA and FRA more accurately reflected short-term blood glucose fluctuations than A1C.

AB - Objective: Evaluate the performance of glycated albumin (GA) monitoring by comparing it to other measures of glycemic control during intensification of antidiabetic therapy. Methods: This 12-week, prospective, multicenter study compared the diagnostic clinical performance of GA to glycated hemoglobin A1C (A1C), fructosamine corrected for albumin (FRA), fasting plasma glucose (FPG), and mean blood glucose (MBG) estimated from self-monitoring of blood glucose (SMBG) and continuous glucose monitoring (CGM) in 30 patients with suboptimally controlled type 1 or 2 diabetes. Results: Mean A1C decreased from 9.5% to 8.1%. Mean SMBG correlated closely with CGM (Pearson r = 0.783 for daily estimates and r = 0.746 for weekly estimates, P<.0001). Both GA and FRA levels significantly correlated with changes from baseline in A1C and mean weekly SMBG (P<.001). The lowest observed median GA occurred at 4 weeks, followed by a small increase and then a slight reduction, mirroring changes in overall mean SMBG values. The median A1C fell throughout the treatment period, failing to reflect short-term changes in SMBG. A ≥1% reduction in GA at 4 weeks was significantly associated with a ≥0.5% change in A1C at 12 weeks (odds ratio [OR] = 19.0, 95% confidence interval [CI]: 1.4, 944, P =.018). Conclusion: In patients receiving glucose-lowering therapy, changes in GA at 4 weeks were concordant with changes in A1C at 12 weeks, and both GA and FRA more accurately reflected short-term blood glucose fluctuations than A1C.

UR - http://www.scopus.com/inward/record.url?scp=85018680546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018680546&partnerID=8YFLogxK

U2 - 10.4158/EP14570.OR

DO - 10.4158/EP14570.OR

M3 - Article

C2 - 26214108

AN - SCOPUS:85018680546

VL - 21

SP - 1195

EP - 1203

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 11

ER -